NASDAQ:DOXAmdocs Stock Price, Forecast & News

Amdocs' stock was trading at $61.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DOX shares have increased by 1.4% and is now trading at $62.26. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amdocs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amdocs.

Amdocs is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Amdocs.

Amdocs Limited (NASDAQ:DOX) posted its quarterly earnings data on Thursday, May, 7th. The technology company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.06 by $0.02. The technology company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.04 billion. Amdocs had a net margin of 11.98% and a return on equity of 16.03%. Amdocs's revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.06 EPS. View Amdocs' earnings history.

Amdocs declared a quarterly dividend on Thursday, May 7th. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.327 per share on Friday, July 24th. This represents a $1.31 dividend on an annualized basis and a yield of 2.10%. The ex-dividend date is Monday, June 29th. View Amdocs' dividend history.

Amdocs issued an update on its third quarter earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of $1.00 to $1.08 for the period, compared to the Thomson Reuters consensus estimate of $1.16. The company issued revenue guidance of $990 million to $1.040 billion, compared to the consensus revenue estimate of $1.05 billion.

5 analysts have issued 1 year price objectives for Amdocs' shares. Their forecasts range from $72.00 to $85.00. On average, they anticipate Amdocs' stock price to reach $76.40 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View analysts' price targets for Amdocs.

News articles about DOX stock have trended somewhat negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amdocs earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news coverage about the technology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAmdocs.

Amdocs saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,700,000 shares, an increase of 5.1% from the April 30th total of 2,570,000 shares. Based on an average daily volume of 1,090,000 shares, the short-interest ratio is presently 2.5 days. Approximately 2.0% of the shares of the stock are sold short. View Amdocs' Current Options Chain.

Some companies that are related to Amdocs include Accenture (ACN), IBM (IBM), Cognizant Technology Solutions (CTSH), Leidos (LDOS), EPAM Systems (EPAM), Booz Allen Hamilton (BAH), Gartner (IT), Caci International (CACI), Mantech International (MANT), Teradata (TDC), Virtusa (VRTU), Unisys (UIS), Forrester Research (FORR), The Hackett Group (HCKT) and Servicesource International (SREV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amdocs investors own include AbbVie (ABBV), Comcast (CMCSA), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Home Depot (HD), Intel (INTC), Pfizer (PFE), Verizon Communications (VZ) and Cisco Systems (CSCO).

Amdocs trades on the NASDAQ under the ticker symbol "DOX."

Amdocs' stock is owned by many different institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (5.10%), Wellington Management Group LLP (4.90%), Wells Fargo & Company MN (4.69%), BlackRock Inc. (3.33%), Massachusetts Financial Services Co. MA (3.22%) and Invesco Ltd. (2.90%).

DOX stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Janus Henderson Group PLC, AJO LP, Morgan Stanley, Morgan Stanley, Citigroup Inc., Wells Fargo & Company MN, and New South Capital Management Inc..

DOX stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, NWQ Investment Management Company LLC, Invesco Ltd., Wellington Management Group LLP, Harel Insurance Investments & Financial Services Ltd., Acadian Asset Management LLC, Robeco Institutional Asset Management B.V., and Schroder Investment Management Group.

Shares of DOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DOX stock can currently be purchased for approximately $62.26.

Amdocs has a market capitalization of $8.39 billion and generates $4.09 billion in revenue each year. The technology company earns $479.45 million in net income (profit) each year or $4.07 on an earnings per share basis. Amdocs employs 24,516 workers across the globe.

The official website for Amdocs is www.amdocs.com.

Amdocs' mailing address is 1390 Timberlake Manor Parkway, Chesterfield MO, 63017. The technology company can be reached via phone at 1 314 212 7000 or via email at [email protected]